logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Pfizer To Acquire Trillium Therapeutics Inc.

Aug 23, 2021•over 4 years ago

Acquiring Company

Pfizer

Acquired Company

Pfizer

New YorkNew Yorkpharmaceuticalspharmaceuticals

Description

Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash. This represents a 118% premium to the 60-day weighted average price for Trillium.

Company Information

Company

Pfizer

Location

66 Hudson Blvd E

New York, New York, United States

About

Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. Seagen is recognized for its advancements in cancer care and plays a significant role in the oncology market. Its dedication to research and development underpins its success in the competitive biotech landscape.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed